Pachymic acid induces apoptosis via activating ROS-dependent JNK and ER stress pathways in lung cancer cells by unknown
Ma et al. Cancer Cell Int  (2015) 15:78 
DOI 10.1186/s12935-015-0230-0
PRIMARY RESEARCH
Pachymic acid induces apoptosis 
via activating ROS-dependent JNK and ER stress 
pathways in lung cancer cells
Jun Ma, Jun Liu, Chunwei Lu and Dingfang Cai*
Abstract 
Background: Pachymic acid (PA), a lanostane-type triterpenoid from Poria cocos, has been reported to possess anti-
emetic, anti-inflammatory, and anti-cancer properties. Nonetheless, the anti-tumor effect of PA in lung cancer cells 
remains unclear. Herein, we report the chemotherapeutic effects and underlying mechanisms of PA against human 
lung cancer.
Methods: The anti-proliferative ability of PA on lung cancer cells was assessed by MTT, colony formation and EdU 
proliferation assays. Flow cytometric analysis was used to detect cell cycle changes. Apoptosis was determined by 
annexin V/PI double-staining and the DNA ladder formation assays. The expressions of the apoptosis-related proteins 
were analysed by western blot. The in vivo efficacy of PA was measured using a NCI-H23 xenograft model in nude 
mice.
Results: PA exhibited anti-tumor effects in vitro accompanied by induction of G2/M phase arrest and apoptosis in 
NCI-H23 and NCI-H460 lung cancer cells. Mechanistically, our data showed that PA induced reactive oxygen species 
(ROS) production, resulting in the activation of both c-Jun N-terminal kinase (JNK) and endoplasmic reticulum (ER) 
stress apoptotic pathways in lung cancer cells. Moreover, blockage of ROS production reversed PA-induced JNK and 
ER stress activation. Finally, PA inhibited the growth of NCI-H23 xenograft tumors without causing any host toxicity, 
and inhibited cell proliferation and induction of apoptosis of tumor cells in tumor xenograft tissues.
Conclusions: In summary, our study demonstrates that PA induces apoptosis through activation of the JNK and ER 
stress pathways in human lung cancer cells. Our findings provide a rationale for the potential application of PA in lung 
cancer therapy.
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Background
Lung cancer is a leading cause of cancer-related deaths 
worldwide [1], and it can be divided into two histological 
groups: non-small cell lung cancer (NSCLC) and small 
cell lung cancer (SCLC). NSCLC accounts for almost 80% 
of lung cancer cases. Although many factors, including 
tobacco smoke, ionizing radiation and viral infection are 
known to increase the risk of NSCLC, the mechanisms 
involved in NSCLC formation remain largely unknown 
[2]. Despite improvements in tumor response to chem-
otherapy, the long-term survival rate for advanced lung 
cancer patients remains quite low [1], calling for a dire 
need of novel strategies to treat lung cancer with more 
active agents [3]. Herbal medicines have long been an 
important source for anti-cancer agents, and some of 
them are currently used in clinical practice [4]. In recent 
years, plant-derived compounds have been extensively 
screened to explore their potential anti-tumor activity. 
A variety of FDA approved anti-tumor agents, including 
docetaxel and topotecan, have demonstrated clinical util-
ity based on ongoing investigations of natural products.
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Exploring the precise molecular mechanisms involved 
in actions of anti-cancer agents has become an important 
approach for anti-cancer drug evaluation and develop-
ment. Among these molecular mechanisms, apoptosis 
is a highly regulated process of cell death that serves to 
eliminate heavily damaged cells without injuring sur-
rounding healthy cells, and its dysregulation underlies 
numerous pathological conditions including cancer 
[5]. Over the years, apoptosis has emerged as the major 
mechanism by which anti-cancer agents act to eliminate 
cancer cells [6]. Recent clinical data has revealed that 
restore deregulated apoptosis in cancer cells by anti-
cancer drugs can significantly improve patient survival 
[7]. In this context, several plant compounds have been 
proven, in a more specific manner, to possess promis-
ing anti-cancer activity through their apoptosis-inducing 
effects [8, 9].
Pachymic acid (PA) is a lanostane-type triterpenoid 
from Poria cocos, also called Fuling, which is an impor-
tant component for treatment of breast cancer metas-
tasis in traditional Chinese medicine. Previous studies 
have shown that PA could induce apoptosis in prostate 
cancer cells [10]. Lots of evidences have revealed that 
certain triterpenoids have anti-cancer activity, especially 
lanostane-type triterpenoids [11, 12]. Another study has 
shown that PA could stimulate glucose uptake through 
enhance GLUT4 expression and translocation [13]. 
Despite the diverse studies conducted to investigate the 
biological activities of PA, the potential of PA against lung 
cancer is poorly defined. In this study, we demonstrated 
that PA induced G2/M phase arrest and cell apoptosis 
in lung cancer cells, via activating ROS-dependent JNK 
mitochondrial and ER stress pathways. PA also exhibited 
anti-tumor ability in vivo without causing any host tox-
icity. Our findings suggest that PA could be a promising 
agent for the treatment of lung cancer.
Results
Pachymic acid (PA) inhibits growth of human lung cancer 
cells in vitro
To explore the biological role of PA in lung cancer, we 
first performed a cell viability assay on NCI-H23 and 
NCI-H460 cells by MTT assay, treated with different 
concentrations of PA (0, 20, 40, 80 and 160 µM) for 24, 48 
and 72 h. As shown in Fig. 1b, PA induced reduction of 
cell growth rate in a concentration- and time-dependent 
manner in both NCI-H23 and NCI-H460 cells. In addi-
tion, we further corroborated these effects by performing 
colony formation assays. After 24 h treatment with differ-
ent concentrations of PA, NCI-H23 and NCI-H460 cells 
were cultured for another 10 days, and colonies counted. 
As shown in Fig.  1c, PA decreased colony formation in 
a concentration-dependent manner. Furthermore, EdU 
incorporation assays showed that the proliferation of 
NCI-H23 and NCI-H460 cells were significantly inhib-
ited by PA relative to vehicle control (Fig.  1d). These 
observations indicated that PA inhibited growth of lung 
cancer cells in vitro.
Pachymic acid (PA) induces G2/M cell cycle arrest 
and apoptosis in lung cancer cells
To examine whether the reduction in cell growth in NCI-
H23 and NCI-H460 cells by PA treatment was related 
to the induction of cell cycle arrest, the lung cancer 
cells were treated with varying concentrations of PA for 
24  h, followed by the cell cycle determination by flow 
cytometry. As shown in Fig.  2a, PA treatment caused a 
concentration-dependent increase of G2/M phase cell 
population in NCI-H23 and NCI-H460 lung cancer cells, 
indicating PA was able to arrest the cell cycle in G2/M 
phase. We further determined whether PA-induced 
cancer cell growth inhibition involved apoptosis. Flow 
cytometry using annexin V-PI staining analysis showed 
that treatment with different concentrations of PA for 
24  h, the proportions of apoptotic cells were markedly 
increased in NCI-H23 and NCI-H460 cells (Fig.  2b). 
Furthermore, the effect of PA on cell apoptosis was 
tested by the DNA ladder formation assay. As shown in 
Fig. 2c, DNA laddering was observed after the NCI-H23 
and NCI-H460 cells treated with PA for 24 h, suggesting 
that PA was able to induce the lung cancer cell apopto-
sis. Taken together, these data suggested that the inhibi-
tion of cell growth by PA associated with the induction of 
G2/M phase arrest and apoptosis.
ROS generation mediates PA‑activated JNK‑mitochondrial 
and ER stress apoptotic pathways
To further investigate the underlying mechanisms 
involved in PA-induced effects on apoptosis in lung can-
cer cells. NCI-H23 and NCI-H460 cells were used for 
the subsequent studies. The mitogen-activated protein 
kinase (MAPK) pathway has been extensively evaluated 
in lung cancer, from the perspective of biomarkers of 
outcome and targets of therapy [14]. Therefore, we first 
focused on MAPK pathway. Surprisingly, we found that 
PA treatment significantly activated all of three path-
ways of MAPKs, including JNK, ERK, and p38 (Fig. 3a). 
We then determined the roles of JNK, ERK, and p38 in 
PA-induced cytotoxicity using specific small-molecule 
inhibitors. NCI-H23 and NCI-H460 cells were pre-
treated with JNK inhibitor SP600125, ERK inhibitor 
PD98059, or p38 inhibitor SB203580, respectively for 1 h, 
then exposed to PA for 24  h. Interestingly, PD98059 or 
SB203580 did not alter the cell viability, but JNK inhibi-
tor SP600125 partially attenuated PA-induced cytotox-
icity, indicating that JNK activation was associated with 
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Fig. 1 Chemical structure of pachymic acid (PA) and its effects on cell growth of human lung cancer cells. a Chemical structure of PA. b NCI-H23 
and NCI-H460 cells were treated with 0, 20, 40, 80 and 160 µM PA for 24, 48 or 72 h, cell viability was measured by MTT assay. Absorbance was read 
at 490 nm with averages from triplicate wells. c, d NCI-H23 and NCI-H460 cells were treated with 0, 20, 40 and 80 μM PA for 24 h, the effect of PA 
on the growth of lung cancer cells was examined by colony formation assay (c) and EdU incorporation assay (d). Data are presented as mean ± SD 
from three independent experiments. *P < 0.05, **P < 0.01 compared with the control group.
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Fig. 2 PA induces cell cycle arrest and apoptosis in human lung cancer cells. a NCI-H23 and NCI-H460 cells were treated with PA (20, 40 or 80 µM) 
for 24 h, and the number of cells in G2/M phase was determined via flow cytometry. b, c NCI-H23 and NCI-H460 cells were treated with PA (20, 40 or 
80 µM) for 24 h, and the cell apoptosis was determined by Annexin V-FITC/PI staining (b) and DNA ladder formation assay (c). Data are presented as 
mean ± SD from three independent experiments. **P < 0.01 compared with the control group.
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Fig. 3 ROS generation mediates PA-activated apoptotic pathways. a NCI-H23 and NCI-H460 cells were treated with PA (20, 40 and 80 µM) for 24 h. 
The protein levels of p-JNK, p-ERK, p-p38, Bcl-2 and Bax were determined by western blot. b NCI-H23 and NCI-H460 cells were pre-treated with 
20 µM JNK inhibitor (SP600125), p38 inhibitor (SB203580), ERK inhibitor (PD98059) for 1 h, or pre-treated with ROS inhibitor NAC (5 mM) for 2 h, then 
exposed to PA (80 µM) for 24 h. Cell viability was determined by MTT assay. c NCI-H23 and NCI-H460 cells were treated with PA (20, 40 and 80 µM) 
for 24 h. The protein levels of ATF4, ATF6, XBP-1 and CHOP were determined by western blot. d NCI-H23 and NCI-H460 cells were pre-treated with 
or without 5 mM NAC for 2 h before exposure to PA (80 μM) for 24 h. The protein levels of p-JNK, Bcl-2, Bax, ATF4, ATF6, XBP-1 and CHOP were deter-
mined by western blot. Data are presented as mean ± SD from three independent experiments. **P < 0.01 compared with the control group.
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PA-induced cell death (Fig.  3b). JNK is a well-known 
regulator in mitochondrial apoptotic pathway [15]. 
We therefore examined the effects of PA on Bcl-2 fam-
ily proteins by western blot analysis, the results showed 
that Bcl-2 level was decreased, whereas Bax level was 
increased in a concentration-dependent manner (Fig. 3a). 
These results suggested that PA-induced NCI-H23 and 
NCI-H460 cells apoptosis is at least partly mediated by 
JNK-mitochondrial pathway.
In addition to mitochondrial pathway, recent advances 
have highlighted the importance of the endoplasmic 
reticulum (ER) in cell death processes. Pharmacological 
interventions that effectively enhance tumor cell death 
through activating ER stress have attracted a great deal 
of attention for anti-cancer therapy [16]. Thus, we next 
examined the expressions of ER stress-related proteins, 
such as transcription factor 4 (ATF4), transcription factor 
6 (ATF6), X-box binding proteins 1 (XBP-1), and C/EBP-
homologous protein (CHOP) in PA-treated NCI-H23 
and NCI-H460 cells. Of note, PA showed concentration-
dependent activation of these four protein expressions 
(Fig. 3c), indicating that PA-induced cell apoptosis is also 
mediated by ER stress pathway.
Previous studies have reported that ROS generation 
could trigger cell apoptosis via activating both mitochon-
drial and ER stress pathways [17, 18]. Therefore, to iden-
tify the role of ROS in mediating anti-tumor effects of 
PA, an ROS inhibitor NAC was used, which is commonly 
used to inhibit ROS production and test ROS induc-
ers, despite some recent studies mentioning that effects 
of NAC in other pathways [24, 25]. As shown in Fig. 3b, 
pre-treated with the NAC for 2 h, then exposed to PA for 
24  h. NAC significantly attenuated NCI-H23 and NCI-
H460 cells death induced by PA. These results indicated 
that ROS production mediated PA-induced cell death. 
Further, we tested the effect of the ROS inhibitor NAC on 
PA-induced activation of JNK and ER stress in NCI-H23 
and NCI-H460 cells by western blot. As shown in Fig. 3d, 
NAC pre-treatment blocked the expression of p-JNK, 
Bax, ATF4, ATF6, XBP-1 and CHOP, and attenuated the 
decrease of Bcl-2 in PA-treated NCI-H23 and NCI-H460 
cells. These results suggested that ROS generation medi-
ated PA-activated apoptotic pathways and was a critical 
upstream regulator in anti-tumor activity of PA.
Anti‑tumor activity of pachymic acid (PA) in vivo
To evaluate the anti-tumor activity of PA in vivo, we used 
human lung cancer NCI-H23 tumor xenograft models. 
As seen in Fig.  4a, PA significantly suppressed tumor 
growth at doses of 30 and 60 mg/kg for 21 days compared 
with the control group. In addition, there is no signifi-
cant difference in body weight change among the vehicle 
group and PA-treated groups (Fig.  4b). Moreover, there 
were no significant differences in the histological findings 
among the treatment and control groups in any of the 
other tissues examined (lung, liver, kidney and spleen) 
(Fig.  4c). These data showed that PA exhibited potent 
anti-tumor activity and high safety in vivo.
Pachymic acid (PA) inhibits proliferation and induces 
apoptosis via activating JNK and ER stress pathways in vivo
To elucidate the mechanisms of PA-meditated anti-
tumor efficacy in vivo, we conducted IHC analysis in the 
NCI-H23 tumor xenograft model. Uncontrolled tumor 
cell proliferation is a characteristic feature of most can-
cers. We therefore analysed the tumor xenografts for the 
potential anti-proliferative effects of PA, using immuno-
histochemical detection of cell proliferation marker Ki-
67-positive cells. As shown in Fig. 5b, PA decreased the 
expression of Ki-67. In addition, to determine whether 
inhibition of tumor growth by administration PA is 
caused by the apoptosis of tumor cells in xenograft tis-
sues, the apoptotic effect of PA on tumor tissues was 
identified by expression of the DNA fragment using 
TUNEL assay. The results showed that there were greater 
numbers of TUNEL-positive cells in the PA-treated 
samples, as compared with the numbers in the non-PA-
treated samples (Fig.  5c). Furthermore, we determined 
the effects of PA on JNK and ER stress pathways in tumor 
xenograft samples. Immunohistochemical analysis sug-
gested that administration of PA resulted in increased 
p-JNK and CHOP in the tumor xenografts (Fig.  5d, e). 
Taken together, consistent with our in  vitro data, the 
above results showed that PA blocked proliferation and 
induced apoptosis via activating JNK and ER stress path-
ways in human lung tumor xenograft model.
Discussion
Lung cancer is the leading cause of cancer-related deaths 
worldwide. Chemotherapy is one of the major treatment 
methods. However, the overall survival rate for advanced 
lung cancer patients is still low [1]. Therefore, the search 
for new anti-tumor agents that are more effective but less 
toxic has become a matter of great interest. Natural prod-
ucts have played an important role as an effective source 
of anti-tumor agents. It is estimated that up to 30–40% 
of the anti-cancer drugs used globally are derived from 
plant sources [19]. Pachymic acid (PA), a lanostane-type 
triterpenoid from P. cocos, is a promising bioactive mol-
ecule that has demonstrated anti-carcinogenic effects in 
some tumor models [10, 20–22]. However, the role of PA 
in lung cancer remains unclear. We therefore undertook a 
comprehensive analysis of the effects of PA on lung can-
cer cells using both in  vitro and in  vivo models. In this 
study, we demonstrated that PA was effective against 
lung cancer cells. Our data also showed that PA induced 
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G2/M phase arrest in NCI-H23 and NCI-H460 lung can-
cer cells. PA-induced G2/M cell cycle arrest provides an 
opportunity for lung cancer cells to undergo apoptotic 
progression. Moreover, annexin V/PI double-staining 
and the DNA ladder formation assays showed that treat-
ment with PA caused concentration-dependent cell 
Fig. 4 PA inhibits tumor xenograft growth in vivo. a Anti-tumor activity of PA in nude mice bearing NCI-H23 tumors. Vehicle control and PA (10, 
30 and 60 mg/kg) were administered for 3 weeks (5 days/week) by ip injection. Tumor volume was monitored. b Body weight of the mice. c H&E 
staining of the paraffin-embedded sections of various tissues (lung, liver, kidney and spleen) obtained from mice were performed to assess whether 
there were any abnormalities caused by the treatment. Scale bars are 100 μm. Data in the graphs represent the mean ± SD (n = 6). **p < 0.01 
versus vehicle control.
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Fig. 5 Mechanisms of anti-tumor activity of PA in vivo. a–e PA was administered for 3 weeks by ip injection to nude mice bearing NCI-H23 xeno-
graft tumors. At the end of the experiments, tumors were excised and processed for H&E staining (a), immunostaining and quantification for Ki-67 
(b), TUNEL (c), p-JNK (d) and CHOP (e). Scale bars are 100 μm.
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apoptosis. These data are consistent with previous report 
that PA induces apoptosis in prostate cancer [10].
A clearer understanding of how PA regulates the cel-
lular death pathway would provide important insights 
into the underlying mechanisms. Therefore, we tried to 
investigate the anti-cancer mechanisms of PA. Mitogen-
activated protein kinases (MAPKs) are serine-threonine 
protein kinases that play major roles in signal transduc-
tion from the cell surface to the nucleus. Studies have 
demonstrated that reactive oxygen species (ROS) are also 
involved in the regulation of different signal transduction 
pathways, including MAPKs and transcription factors 
[23]. In the present study, we found that treating NCI-
H23 and NCI-H460 lung cancer cells with PA increased 
the levels of all three pathways in MAPKs. Surprisingly, 
only JNK activation is involved in PA-mediated cell 
death. In addition, considerable evidences suggested that 
JNK is primarily activated by various environmental fac-
tors including oxidative stress [24]. Our data also showed 
that ROS blockage inhibited PA-induced JNK phospho-
rylation, indicating that PA-induced apoptosis through 
ROS-dependent JNK apoptotic pathway. Moreover, it has 
been well known that activation of JNK pathway induces 
mitochondria-dependent cell apoptosis via activating 
mitochondrial Bcl-2 family proteins [25]. We found that 
PA stimulation significantly increased the level of pro-
apoptotic Bax and decreased the level of anti-apoptotic 
Bcl-2 in NCI-H23 and NCI-H460 cells. Furthermore, we 
showed that PA-induced activation of Bcl-2/Bax pathway 
was blocked by ROS inhibitor NAC, indicating that ROS 
acts as upstream signaling molecules involved in PA-
induced activation of mitochondrial pathway.
It is well documented that in response to oxidative 
stress mediated by ROS, accumulation of unfolded or 
misfolded proteins triggers a cellular adaptive procedure 
known as ER stress [26]. Cells initially adapt to the accu-
mulation of unfolded proteins by inducing the expres-
sion of ER-resident molecular chaperones as well as by 
inhibiting nascent protein synthesis [27]. However, if 
this adaptation does not prove sufficient, the apoptotic 
response is initiated via induction of ER-associated apop-
totic molecules. Among the ER-stress related proteins, 
ATF4, ATF6 and XBP-1 are typical ER stress-regulated 
proteins involved in ER stress-induced apoptosis [26, 28]. 
Previous studies have demonstrated that the regulation 
of ROS on ER stress activation in a variety of cancer cell 
lines, including lung cancer cell [29–31]. Additionally, it 
has been reported that growth inhibition and induction 
of apoptosis by PA in gemcitabine-resistant pancreatic 
cancer cells were associated with ER stress activation 
both in vitro and in vivo [32]. In agreement with previ-
ous reports, our findings showed that ATF4, ATF6 and 
XBP-1 were induced in a dose-dependent manner after 
PA stimulation, suggesting that ER stress is activated 
after PA treatment. These initiations of ER stress apop-
totic pathway have been reported to increase CHOP 
gene expression, triggering ER stress-specific cascade for 
implementation of apoptosis [33]. Consequently, the up-
regulation of CHOP protein expression was observed in 
NCI-H23 and NCI-H460 cells after PA treatment. More-
over, we found that PA-induced activation of ER stress 
was blocked by ROS inhibitor NAC, indicating that ROS 
production is also the upstream regulator of PA-induced 
ER stress in lung cancer cells.
Although in  vitro cell culture models are a good sys-
tem for preliminary screening of the effects of chemo-
therapeutic agents; the observations must be verified 
in  vivo using animal models, prior to consideration 
of their potential use in humans. We therefore used an 
in  vivo model of xenografts of NCI-H23 tumor cells in 
nude mice to verify the chemotherapeutic potential of 
PA against lung cancer cell growth. Our study provided 
evidence that administration of PA inhibited the growth 
of NCI-H23 tumor xenografts without any apparent sign 
of toxicity in the mice. These data are in accordance with 
the decreased proliferation documented by Ki67 immu-
nostaining. Additionally, PA induced apoptosis as indi-
cated by TUNEL staining in tumor tissues, at least in 
part, by activating JNK and ER stress apoptotic pathways. 
These in  vivo results are consistent with our in  vitro 
study, which further suggests that PA may be an applica-
ble approach to enhance the anti-tumor activity against 
lung cancer.
Conclusion
The present study demonstrates that PA activates ROS-
dependent JNK and ER stress apoptotic pathways, and 
invokes strong anti-cancer activity against lung cancer by 
inducing apoptosis as well as inhibiting cell growth/pro-
liferation. Thus PA appears to be an potentially attractive 
bioactive phytochemical for lung cancer treatment.
Methods
Antibodies and reagents
Antibodies specific for p-JNK, JNK, Bcl-2, Bax, Ki67, 
β-actin and the secondary antibodies were purchased 
from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-
bodies specific for CHOP, ATF4, ATF6, p-ERK, ERK, 
p-p38 and XBP-1 were purchased from Cell Signaling 
Technology (Danvers, MA). Annexin V-fluorescein iso-
thiocyanate (FITC)/propidium iodide (PI) apoptosis 
detection kit was supplied by Biouniquer Tech (Nanjing, 
China). SP600125, SB203580, PD98059 and N-acetyl-
cysteine (NAC) were purchased from Sigma (St. Louis, 
MO). Pachymic acid (Fig.  1a) was purchased from 
Chengdu Biopurify Phytochemicals Ltd. (Chengdu, 
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Sichuan, China). Other chemicals were obtained from 
Sigma (St Louis, MO).
Cell culture
The human lung cancer cell lines NCI-H23 and NCI-H460 
were purchased from American Type Culture Collection 
(Rockville, MD), and cultured as recommended as mon-
olayers in DMEM medium (GibcoBRL Life Technologies, 
Grand Island, NY) supplemented with 10% fetal bovine 
serum (FBS; GibcoBRL Life Technologies) and 1% penicil-
lin–streptomycin-neomycin (GibcoBRL Life Technologies), 
in a humidified incubator at 37°C in a 5% CO2 atmosphere.
MTT assay
Cell viability was analyzed using 3-(4,5-dimethylthi-
azol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
assay. Cells were seeded in 96-well plates at a density of 
1,000–1,500 cells/well and were treated with PA at the 
indicated dose for 24, 48 or 72 h. Approximately 20  μl of 
MTT (5 mg/ml; Sigma, St Louis, MO, USA) was added to 
each well and incubated for 4 h. At the end of incubation, 
supernatants were removed, and 150 μl of dimethylsul-
foxide (Sigma) was added to each well. The absorbance 
value (optical density) of each well was measured at 
490 nm. All experiments were performed thrice.
Colony formation assay
Cells were plated in 6-well culture plates at 600 cells/
well. Each cell group had two wells. Cells were treated 
with PA at the indicated dose for 24 h. After incubation 
for another 10 days at 37°C, cells were washed twice with 
phosphate buffered saline and stained with hematoxylin 
solution. The number of colonies containing >50 cells 
was counted under a microscope. The colony formation 
efficiency was calculated as (number of colonies/num-
ber of cells inoculated) × 100%. All assays were indepen-
dently performed in triplicate.
EdU proliferation assay
The proliferation of NCI-H23 and NCI-H460 cells were 
examined using the Cell-Light EdU Apollo488 In vitro 
Imaging Kit (RiboBio) according to the manufacturer’s 
protocol. Briefly, cells were incubated with 10 μM EdU for 
2 h before fixation with 4% paraformaldehyde, permeabili-
zation by 0.3% Triton X-100 and EdU staining. Cell nuclei 
were stained with 5  μg/ml DAPI (4′,6-diamidino-2-phe-
nylindole) for 10 min. The number of EdU-positive cells was 
counted under a microscope in five random fields (×100). 
All assays were independently performed in triplicate.
Cell cycle and apoptosis assay
Flow cytometric analysis was performed to determine 
the presence of cell cycle arrest and apoptotic cells. After 
treatment with PA for 24  h, the cells were collected by 
trypsinisation and washed twice with PBS, fixed in ice-
cold 80% ethanol, and stored overnight at 4°C. For analy-
sis, the cells were washed twice with PBS and 10 mg/ml 
RNase A was added. Propidium iodide was added to the 
tubes at a final concentration of 0.05  mg/ml and incu-
bated at 4°C for 20  min in the dark. Cell cycle analysis 
was performed with FACSCalibur flow cytometer (BD 
Biosciences, CA). FITC-labeled Annexin V/PI staining 
was performed according to the manufacturer’s instruc-
tions (Keygen, Nanjing, China). Briefly, 1 × 106 cells/well 
were suspended in buffer containing FITC-conjugated 
Annexin V/PI at appropriate concentrations. The sam-
ples were analyzed by flow cytometry and 20,000 events 
from each sample were obtained to ensure adequate data.
DNA fragment analysis
The cells (1.5  ×  106) were treated with PA (20, 40 or 
80  µM) for 24  h, then collected and washed twice with 
PBS. DNA was extracted using the Genomic DNA Mini 
Preparation kit with Spin Column (Beyotime Institute 
of Biotechnology, Haimen, China). DNA (~15  μg) was 
loaded onto a 1.5% agarose gel. Subsequent to electro-
phoresis, the gel was visualized using ethidium bromide 
staining under ultraviolet light.
Western blotting
Cells were seeded in 6-well plates at a density of 1 × 106 
cells/well with 2 ml completed DMEM medium. Follow-
ing PA treatment for the indicated times, total protein 
was extracted. The protein concentration was determined 
using the BCA method. Equal quantities of proteins were 
separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred by elec-
troblotting onto a nitrocellulose membrane. Membranes 
were incubated with the primary antibody at 4°C over-
night. After additional TBST washes, membranes were 
incubated with corresponding horseradish peroxidase-
conjugated secondary antibodies (Bio-Rad) for 1  h at 
room temperature and detected by the enhanced chemi-
luminescence method (SuperSignal West Pico substrate; 
Pierce; Rockford, IL).
Tumor xenograft model
All procedures and experiments involving animals in this 
study were performed in accordance with the National 
Institutes of Health Guide for Care and Use of Labora-
tory Animals. The study protocol was approved by the 
Animal Ethics Committee at Fudan University, China. 
Female athymic nude mice of 4–5 weeks of age were pur-
chased from Shanghai SLAC Laboratory Animal Co., 
Ltd. (Shanghai, China) and were housed in the Animal 
Resource Facility. Exponentially growing NCI-H23 cells 
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(5 × 106 in 100 µl PBS) were injected subcutaneously in 
the right flank of each mouse. Tumor xenografts were 
allowed to grow to an average size of 100–200  mm3 
and were randomly assigned to four different treatment 
groups (six mice per group): (a) vehicle control (0.1% 
DMSO in physiological saline); (b) PA 10 mg/kg; (c) PA 
30  mg/kg; (Dd) PA 60  mg/kg. The mice were adminis-
tered PA via intraperitoneal (ip) injections for 3  weeks 
(5  days/week). Tumor size was measured on two axes 
with the aid of Vernier calipers and tumor volume (mm3) 
was calculated using the formula: 1/2(L × W2) where L is 
the longest and W is the shortest axis. Mice were eutha-
nized at the end of the study and/or when tumor size 
exceeded 2,000 mm3. At the end of the experiments, the 
xenograft tumors, lungs, livers, kidneys and spleens were 
removed from the mice and snap-frozen for immunohis-
tochemistry and hematoxylin and eosin staining.
TUNEL assay for apoptotic cells
The type of cell death (necrosis/apoptosis) was evalu-
ated by the terminal deoxynucleotidyl transferase-medi-
ated deoxyuridine biotin nick-end labeling (TUNEL) 
assay with an Apo-Direct kit (Pharmingen, San Diego, 
CA). Briefly, after antigen retrieval, the tumor sec-
tions (4 µm-thick) were fixed by incubation with 4% par-
aformaldehyde at 4°C. The permeabilized sections were 
incubated with terminal deoxynucleotidyl transferase 
recombinant (rTdT) enzyme-catalysed reaction and 
nucleotide mixture for 60 min at 37°C in the dark. After 
immersion in stop/wash buffer for 15 min at room tem-
perature, the sections were washed with PBS to remove 
unincorporated fluorescein-12-dUTP and the nuclei 
counterstained with hematoxylin.
Hematoxylin and eosin (H&E) staining 
and immunohistochemistry
The xenograft tumors, lungs, livers, kidneys and spleens 
were performed hematoxylin and eosin staining. Briefly, 
freshly dissected tissues were fixed and embedded in 
paraffin. After being cut into 4-μm slices, the sections 
were deparaffinized and stained in Mayer’s Hematoxy-
lin and Eosin solution. Finally, the sections were dehy-
drated and mounted with Permount in a fume hood. The 
results were analyzed under a phase-contrast Olympus 
microscope (Olympus America Inc). For the immuno-
histochemical studies, the freshly dissected tumor tissue 
was fixed in 10% neutral buffered formalin for 24–48 h. 
The tissue block was embedded in paraffin and cut to 
the desired thickness using a microtome, and was affixed 
onto a slide. After several wash cycles, the tumor sec-
tions were blocked and incubated with antibodies against 
Ki67, p-JNK and CHOP (diluted 1:200 in 5% horse serum 
in PBS) overnight at 4°C. Subsequently, sections were 
incubated with pre-diluted streptavidin-peroxidase HRP 
conjugates in a humidified chamber at room tempera-
ture using a staining kit, according to the manufacturer’s 
instructions (Dako North America, Inc., CA). The sec-
tions were counterstained with hematoxylin for 2–3 min 
and mounted and analyzed under a phase-contrast 
Olympus microscope (Olympus America Inc).
Statistical analysis
Data are presented as mean ± SD unless otherwise indi-
cated. The statistical significance of the difference between 
the values of control and treatment groups was deter-
mined by either Student t test or simple one-way ANOVA 
followed by Tukey’s post hoc test for multiple comparisons 
using Prism version 5 (GraphPad Software, Inc.). Values of 
p < 0.05 were considered statistically significant.
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